cnb791 ht logo promo |

Introducing the new PhysioMimix Single-Organ Higher Throughput System

Learn more
CN Bio logo CN Bio logo CN Bio logo CN Bio logo
  • Products
    • Explore our solutions


      PhysioMimix® products enable you to recreate complex human biology and accurately predict human drug responses

      PhysioMimix OOC

      PhysioMimix OOC systems
      Learn more

      Consumables

      • Multi-chip plates
      • 3D validated cells
      • NASH-in-a-box
      Learn more

      Models

      • Single-organ models
      • Multi-organ models

      Support packages

      • PhysioMimix® support packages
  • Applications
    • Discover the applications


      Investigate the application areas that our PhysioMimix® products and services support

      Learn more

      Disease modeling

      • Non-Alcoholic Steatohepatitis
      • Hepatitis B
      • Oncology
      • COVID-19
      Learn more

      Safety toxicology

      • Drug-induced liver injury
      • Immune-mediated toxicities
      Learn more

      ADME

      • Drug absorption
      • Drug metabolism
      • Drug bioavailability
      Learn more
  • Services
    • Studies as a service


      Our team will work collaboratively with you to design a study around your research goals and generate actionable data within weeks

      Learn more
      NAFLD / NASH icons

      NAFLD / NASH

      Drug-induced liver injury icon

      Drug-induced liver injury

      icon adme |

      ADME

      Oncology icon

      Oncology

  • Resources
  • Company
    • About us


      Meet the team, explore our culture and discover what to expect when working with us

      CN Bio team photo
      About us

      Latest news

      • Immune-mediated DILI – Predicting the unpredictable!

      • CN Bio appoints Deepak Singh as Vice President of Sales and Marketing

      • CN Bio extends microphysiological system portfolio with PhysioMimix Single-Organ Higher Throughput System  

      View all news

      Upcoming Events

      • SLAS Europe 2023

      • SOT 2023

      • WORD 2023

      • MPS World Summit 2023

      View all events

      Join the team!

      • Doctoral Researcher (Horizon Marie Curie Doctoral Network Project)

      View all jobs
  • Contact
  • Products
    • PhysioMimix® OOC Microphysiological Systems
    • Consumables
      • PhysioMimix® multi-chip plates
      • 3D validated cells
      • NASH-in-a-box
    • Organ-on-a-chip models
    • Support packages
  • Applications
    • Disease modeling
    • Safety toxicology
    • ADME
  • Services
    • Non-Alcoholic Steatohepatitis
    • Drug-Induced Liver Injury
    • ADME
  • Resources
  • Company
    • About us
    • Events
    • News
    • Careers
  • Contact
  • Skip to main content
  • Skip to footer
Chat live with an expert

Promotion of Dr David Hughes to the role of Chief Technology Officer

July 14, 2014 by CN Bio

Dr David Hughes Chief Technology Officer CN Bio Innovations

Dr David Hughes has been promoted to the role of Chief Technology Officer, effective immediately. In his new role, he will take responsibility for overseeing management of all technical projects and alliances with CN Bio partners. He will also continue to manage the internal scientific and engineering teams.

Dr Hughes joined the Company in 2010 as Head of Engineering and was promoted to Technical Director in February 2013. He has been pivotal in securing contracts with leading pharmaceutical companies and has been lead principal investigator on several UK, EU and US grants including currently the EU FP7 BIO-MIMETICS project. As co-principal investigator on a $26 Mi US DARPA contract, Dr Hughes has contributed to the strategic direction of this program as well as leading the company’s participation and delivery of milestones under the contract. Prior to joining CN Bio, Dr Hughes graduated from the University of Oxford with a Masters in Engineering Science and Doctorate in Chemical Engineering. After that he spent three years in industry at GSK.

Dr David Scales, CEO of CN Bio said: “The Board are delighted to make this appointment in recognition of the outstanding contribution David has made to the company’s technical progress over the past year or so. He will now take a senior leadership role at an important new phase for the company as we enter a number of key academic and industrial collaborations. I welcome David’s continued commitment and energy for the business.”

Category iconBusiness

Speak to our experts

Speak directly with one of our OOC experts to see how our products and services can support your studies

Request a meeting

Footer

CN Bio logo

332 Cambridge Science Park, Milton Road
Cambridge, CB4 0WN

UK: +44 (0) 1223 737 941

US: +1 415 523 4005

Privacy | Cookies | Terms | Regulatory | Accessibility

©2023 CN Bio Innovations Ltd
Registered No. ‍06517359. VAT No. 978184563

Latest news

  • Immune-mediated DILI – Predicting the unpredictable! March 16, 2023
  • CN Bio appoints Deepak Singh as Vice President of Sales and Marketing March 14, 2023
  • CN Bio extends microphysiological system portfolio with PhysioMimix Single-Organ Higher Throughput System   February 27, 2023

Upcoming events

MPS World Summit 2023 June 26-30, 2023

SLAS Europe 2023 May 22-26, 2023

SOT 2023 March 19-23, 2023

WORD 2023 March 22, 2022